Introduction
Optimal symptom control for patients with advanced cancer depends upon a detailed analysis and diagnosis of the underlying causes and careful selection of appropriate therapeutic manoeuvres individualized for each patient. Hospices and other specialized units have been established in recent years and have produced clear recommendations for the management of pain and other symptoms1"2'3. There is, however, little published data on the resultant patterns of drug use and the relative importance of other therapeutic options in the management of symptoms due to advanced cancer.
A retrospective review of the treatments received by patients admitted to the Continuing Care Unit of the Royal Marsden Hospital, Sutton, has been carried out. The review covers the first year of operation of the unit and provides information on the patterns of drug use and the importance ofmore specific therapies in these patients. Patients and methods Between January 1986 and January 1987 there were 233 admissions to the 13-bed Continuing Care Unit at this hospital. Patients are referred to the unit solely from within the Royal Marsden Hospital, and the emphasis is on active symptom control and rehabilitation. Admissions are both by transfer from other wards in the hospital and, following discharge or outpatient referral, from home. Of 168 patients admitted to the unit for the first time in the year of study, 97 (58%) were subsequently discharged home and 128 (76%) ultimately died as inpatients in the unit.
The case records of 158 patients admitted in this period have been reviewed, the remaining 10 records being unavailable or lost at the time of analysis. Details of the patients and the treatment they received whilst inpatients have been analysed.
Results
Clinical details ofthe 158 patients analysed are shown in Table 1 and the pattern of oral analgesic and coanalgesic use in Table 2 . Twenty-seven patients (17%) Continuing Care Unit, received no morphine during their admission, their symptoms being adequately controlled with simple (non-opioid) or moderate (mild opioid) analgesics together with appropriate co-analgesics. In 5 patients a combination of co-proxamol with additional paracetamol was given, in 6 paracetamol was used in combination with morphine and in 7 patients co-proxamol was used as breakthrough analgesia in patients on morphine.
Of the 131 patients who received morphine, 4 used suppositories and one had oxycodone suppositories substituted for oral morphine. When given orally, morphine elixir was used for most patients (aqueous morphine sulphate solution containing EDTA and sodium metabisulphite as preservatives). Thirty patients (23% of those receiving morphine) had morphine in slow release formulation (MST Continus) at some time during their admission. In 10 patients, MST was the only morphine preparation used. Four patients were taking oral diamorphine tablets at the time of referral. The only other strong opioid drug to be used regularly was dextromoramide, which 3 patients received as a short-acting top-up analgesic to cover painful dressing changes. One patient was taking pethidine and one methadone at the time of referral. The former was changed to morphine and the latter continued with methadone. All other patients who required a strong opioid analgesic and were able to take oral medication were managed with oral morphine.
Details of both the modal dose of morphine and the maximum dose received by the 131 patients requiring morphine are shown in Figure 1 . In 65% of patients a modal 4-hourly dose of less than 40 mg was required and in 51% a maximum 4-hourly dose of less than 40 mg was given. Only 11% required doses greater than 120 mg 4-hourly. Sixty-one patients who received morphine had either renal impairment (serum creatinine > 120 mmol/l), hepatic impairment (alanine transaminase > 30 iu/l or GGT >50 iu/1) or both. Table 3 shows that the median doses of morphine (both modal and maximum) were lower in patients with renal and hepatic impairment compared with those with normal function, though the differences did not achieve statistical significance. In contrast, a highly significant inverse relationship between morphine dose requirement and age was seen ( Table 4) .
Parenteral diamorphine was given to 85 patients (54%). The indication for parenteral administration in these patients was inability to take oral medication or suppositories. In 76 of the 85 patients (89%) this was due to deteriorating levels of consciousness in the final hours before death, in 8 (9%) intestinal obstruction was present, and in one case parenteral medication was used because of intolerance to high doses of oral morphine. Where patients were judged to be close to death diamorphine was administered by intermittent subcutaneous injection. In the 59 patients who received diamorphine in this way a median of one dose and mean of 2.3 doses (range 1-12) was required, median survival from the initiation of diamorphine being 12 h (range 2-48 h). To avoid multiple injections in patients with longer life expectancy a subcutaneous infusion was used in 26 patients. In two patients with sub-acute intestinal obstruction the duration of infusion was 4 weeks and 3 months, respectively. In the remaining 24 patients the median duration was 96 h, and the mean 49.8 h (range 12-192 h).
Hyoscine by injection was given with diamorphine to ameliorate respiratory symptoms from retained secretions in 54 patients (34%) and one patient received an infusion over 4 days. When given by injection the median number of injections required was one, mean 3.6 (range 1-20).
Non-steroidal anti-inflammatory drugs (NSAIDs) were selected for those patients with bone pain or other musculoskeletal pain. In the 40 patients receiving these drugs, 24 were given flurbiprofen, the drug of first choice in this unit, 7 received ibuprofen, 3 benorylate, 2 naproxen, one diclofenac and 3 patients received indomethacin by suppository. The indications for steroids in the 67 patients receiving them were spinal cord compression 4 (6%), nerve root compression 11 (16%), cerebral metastasis 10 (15%), soft tissue infiltration 20 (30%), anti-emetic 8 (12%), and for nonspecific effects 14 (21%). Fifty-three patients received dexamethasone, our steroid ofchoice, the remaining 14 having been started on prednisolone prior to referral.
A total of 78 patients (48%) received anti-emetic drugs. Ofthe 131 patients receiving morphine, 74 (56%) required an anti-emetic. Thirty-nine of these patients were female and 35 male. Twelve patients required a combination of drugs, 11 receiving 2 drugs, and 1 patient receiving 3 drugs. The commonest antiemetics to be used were haloperidol (35 patients), cyclizine (22 patients) and metoclopramide (21 patients).
Many patients also received specific tumoricidal therapy for symptom control. Twenty-one patients (13%) were treated with radiotherapy. The indications for this were bone pain 11, cerebral metastasis 3, spinal cord compression 2, pelvic mass 2, painful skin nodule 1, primary cerebral tumour 1, and base of skull infiltration 1. Twenty-three patients (14.6%) received hormone therapy. These were principally patients with breast cancer (11 patients), prostate cancer (3 patients) and renal cancer (3 patients). Tamoxifen was the most commonly used drug (11 patients), followed by medroxyprogesterone (5 patients) and aminoglutethimide (3 patients). Six patients (3.7%) received chemotherapy: 3 had 5FU for colo-rectal cancer, one had 5FU, adriamycin and mitomycin C for carcinoma of the stomach, one carboplatin for a paraganglioma, and one tumour necrosis factor for lung cancer. Five patients had surgical procedures performed: 2 had Nottingham tubes passed for obstructive dysphagia, 2 had internal fixation of a bone (in one case prophylactically and in the other after pathological fracture) and one patient had examination under anaesthetic and cystoscopy. In addition, two patients had dental procedures under general anaesthetic.
Other pain relieving measures were also employed in selected patients. Twenty-one (13%) received treatment with a graduated compression sleeve (Lymphapress) for lymphoedema. Transcutaneous nerve stimulation, acupuncture and relaxation were given to some patients but accurate figures for their use are not available. Only one patient had a specific nerve blocking procedure; a coeliac plexus block for pain and nausea resulting from a primary carcinoma of the pancreas.
Discussion
The data presented demonstrate the wide range of therapeutic options available to control the symptoms of advanced cancer. The use of a simple analgesic ladder escalating from paracetamol to co-proxamol or dihydrocodeine and then to morphine has meant in practice that only a limited number of analgesic drugs were used. Seventeen per cent of patients achieved good symptom control without the use of morphine or any other strong opioid analgesic. This may reflect in part the fact that pain was a presenting symptom on admission in only 127 patients (80%), although this is more than balanced by the finding that the prime indication for morphine in 29 patients (22%) was relief of respiratory symptoms rather than pain.
The pattern of morphine dosage is similar to that reported in other published data45. In one series, 67% of patients required a maximum 4-hourly dose of less than or equal to 30 mg in contrast to 40% in this study, and 2% required a maximum 4-hourly dose of greater than 200 mg compared to 7% in this study. Other studies have reported only maximum doses whilst the modal doses seen here demonstrate that much lower doses were required for most ofthe period that the patient required morphine. Approximately one-quarter ofpatients received slow-release morphine tablets. These were used once a patient's pain had been controlled on a stable dose of 4-hourly morphine elixir, and they provided a highly convenient means of delivering regular morphine. In patients who were starting morphine or who required frequent dose adjustments, however, this formulation was unsatisfactory and 4-hourly elixir was preferred.
The relatively small percentage of patients receiving MST was a reflection of the fact that this was an inpatient population, often with difficult pain problems or an otherwise unstable clinical state. MST may have a greater application in a stable outpatient population.
A previous report has examined the influence of renal and hepatic impairment on morphine requirements and found much lower median dose requirements (in terms of maximum doses) in patients with renal but not hepatic impairment6. These data were not subjected to statistical analysis. Our data show that although lower median doses were required, in this case for both renal and hepatic impairment, there was wide individual dose variation and the differences were not statistically significant. In contrast, a highly significant effect of age can be seen with much higher morphine dose requirements in younger patients. The explanation for this is not clear. It may reflect a more marked affective component to chronic cancer pain in younger patients making pain control more difficult, although a similar effect has also been observed in acute postoperative pain7. Pharmacokinetic data suggest that the disposition of morphine in the elderly is altered with a much smaller volume of distribution which may account to some extent for their lower dose requirements8.
True intolerance to oral morphine is rare if side effects are anticipated and prevented. Three of our patients had particular difficulties: one was troubled by persistent nausea and vomiting, and 2 by excessive drowsiness. In these patients, conversion to a subcutaneous diamorphine infusion (one patient) or oral phenazocine (2 patients) proved effective in reducing side effects but maintaining pain control. All other patients who required a strong opioid analgesic and were able to take oral medication were managed with oral morphine.
Previous reports have indicated that 69%1 and 51%9 of patients have required parenteral diamorphine before death. In our series the figure was 54%.
Spinal opioid administration is not used in this unit and the evidence to date does not support any particular advantage for this route of administration'0, except in rare situations when patients are unable to tolerate any strong opioid given systemically. Only 49% of all patients required an anti-emetic and of those receiving morphine, 56%. This proportion is lower than reported previouslyll""2 and supports the policy of close surveillance of inpatients, with immediate introduction of anti-emetics where symptoms arise, rather than routine administration in all patients. The proportion of patients receiving combination anti-emetics is similar to that reported by Hanks" and significantly lower than the series from St Christopher's Hospice12. This latter report also showed that a greater proportion of females required anti-emetics though this was not apparent in the Oxford data"l, and in the present series the sex incidence was approximately equal.
Co-analgesics were used to enhance the pain control provided by conventional analgesia in 124 patients (78%). The significant affective component of chronic cancer pain is reflected in the relatively high proportion of patients receiving an antidepressant or anxiolytic drug. As far as NSAIDs are concerned, their use was reported in 14.5% of 643 patients at St Christopher's Hospice9 compared with 25% of the 158 patients in this series. A fundamental difference between this continuing care unit and a hospice is its place as an integral part of the hospital, benefiting from close and easy access to specialist oncological teams. This is reflected in the considerable proportion of patients who had specific tumoricidal therapy either initiated or continued whilst in the unit. In each case this was for control of specific symptoms. In total 46 patients (29%) received either radiotherapy, hormone therapy, chemotherapy or had surgery. This contrasts with data from St Christopher's Hospice reporting the use of radiotherapy in 5% of inpatients'3, hormone therapy in 6% and chemotherapy in 1.6%14. This finding may have implications when considering both the optimum environment for units specializing in symptom control for advanced cancer and the training of those wishing to enter this field.
This retrospective study confirms that for most patients with pain due to advanced cancer, a simple therapeutic regimen using a three step analgesic ladder and a limited number of co-analgesic drugs is appropriate. In addition, almost one-third of patients benefited from specific selected anti-tumour therapy. In particular radiotherapy or hormone therapy can be used to optimize symptom control without additional treatment-related toxicity.
